Cervical screening is our flagship, and for good reason. But a health plan does not have just one gap to close. The members overdue for cervical screening are frequently overdue for colorectal, diabetes, and kidney screening too. The question is whether you run four programs with four vendors, or one program that closes them together.
The same at-home infrastructure that delivers HPV self-collection also delivers the rest of the preventive menu. Colorectal cancer screening uses an at-home fecal immunochemical test (FIT), closing the COL measure. Diabetes monitoring uses an at-home HbA1c, addressing GSD, a measure triple-weighted in Medicare Advantage Star Ratings. Kidney health uses at-home eGFR and uACR to support the Kidney Health Evaluation, or KED. Chlamydia screening (CHL) and biometric screening round out the core menu, with additional molecular and clinical testing available from our lab.
Running these together, rather than as separate vendor relationships, has three advantages. You get one clean, connected dataset instead of handoffs between systems. You get one accountable partner instead of four to manage. And you get one owned laboratory processing everything, so quality and reporting stay consistent across measures.
There is also a member-experience benefit. A member who is engaged for one screening is far easier to engage for the next. A single, coordinated outreach relationship closes more gaps per member than disconnected campaigns ever will, which is exactly what moves both quality scores and outcomes.
Cervical is where SNT Biotech leads, but it is not where we stop. Closing CCS, COL, GSD, KED, and more on one platform is how a plan turns a single successful program into a measurable lift across its whole quality picture.
See how one platform closes your whole screening menu.